Drug Profile
NP 10679
Alternative Names: NP-10679Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator NeurOp
- Class Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Pain; Subarachnoid haemorrhage
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Subarachnoid-haemorrhage(In volunteers) in USA (IV, Infusion)
- 10 Dec 2021 Clinical development is ongoing in Subarachnoid-haemorrhage(In volunteers) in USA (IV, Infusion)
- 10 Dec 2021 Neurop plans a phase II trial in Subarachnoid hemorrhage in 2023